Cargando…
Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, mostly due to its resistance to treatment. Of these, checkpoint inhibitors (CPI) are inefficient when used as monotherapy, except in the case of a rare subset of tumors harboring microsatellite instability (< 2%). This ineff...
Autores principales: | Hilmi, Marc, Bartholin, Laurent, Neuzillet, Cindy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5974576/ https://www.ncbi.nlm.nih.gov/pubmed/29853732 http://dx.doi.org/10.3748/wjg.v24.i20.2137 |
Ejemplares similares
-
Neoadjuvant Treatments for Pancreatic Ductal Adenocarcinoma: Where We Are and Where We Are Going
por: Coppola, Alessandro, et al.
Publicado: (2023) -
Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go?
por: Wang, Chenqi, et al.
Publicado: (2022) -
Immune Therapy for Liver Cancers
por: Hilmi, Marc, et al.
Publicado: (2019) -
Targeting therapy in pemphigus: Where are we now and where are we going?
por: Abulikemu, Kailibinuer, et al.
Publicado: (2023) -
CAR-T cell therapy: Where are we now, and where are we heading?
por: Wang, Jia-Yi, et al.
Publicado: (2023)